Evidence map›Paper›PMID 41640617›Full record

ArticleWorld journal of gastroenterology2026

Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection.

Jeayeon Park, Jae Yoon Jeong, Soon Sun Kim, Jae Hyun Yoon, Hyuk Soo Eun, Jonggi Choi, Ki Tae Yoon, Young Kul Jung, Soo Young Park, Geum-Youn Gwak and 6 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jeayeon ParkDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea.
Jae Yoon JeongDepartment of Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul 07985, South Korea.
Soon Sun KimDepartment of Gastroenterology, Ajou University School of Medicine, Suwon 16499, Gyeonggi-do, South Korea.
Jae Hyun YoonDepartment of Gastroenterology and Hepatology, Chonnam National University Hospital and Medical School, Gwangju 61469, South Korea.
Hyuk Soo EunDepartment of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon 35015, South Korea.
Jonggi ChoiDepartment of Internal Medicine, Asan Medical Center, Seoul 05505, South Korea.
Ki Tae YoonDepartment of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan 50612, South Korea.
Young Kul JungDepartment of Internal Medicine, Korea University College of Medicine, Seoul 02841, South Korea.
Soo Young ParkDepartment of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu 41944, South Korea.
Geum-Youn GwakDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea.
Do Young KimDepartment of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, South Korea.
Ji Hoon KimDepartment of Internal Medicine, Korea University College of Medicine, Seoul 02841, South Korea.
Jin-Woo LeeDepartment of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon 22212, South Korea.
Tae Yeob KimDepartment of Internal Medicine, New Hope Internal Medicine Clinic, Seoul 03113, South Korea.
Jeong Won JangDepartment of Internal Medicine, The Catholic University of Korea, Seoul 06591, South Korea.
Su Jong YuDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea. ydoctor2@snu.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver recent decades, treatment for human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection has significantly advanced. HIV is known to accelerate liver disease progression and increase liver-related mortality in patients with HCV infection.

aimTo reassess the effectiveness of HCV treatments by comparing outcomes between HIV/HCV co-infected and HCV mono-infected patients.

methodsWe retrospectively included patients with HCV mono-infection or HIV/HCV co-infection at 12 tertiary referral centers from January 2009 to December 2020. The primary endpoint was overall survival (OS). Secondary endpoints included achievement of a sustained virologic response (SVR), time-to-occurrence of hepatocellular carcinoma (HCC), and the changes in fibrosis-4 (FIB-4) index.

resultsA total of 904 patients were included: 792 with HCV mono-infection and 112 with HIV/HCV co-infection, of whom 97 (86.6%) had received prior HIV treatment. HCV treatment was administered to 741 (93.6%) mono-infected and 86 (76.8%) co-infected patients. Among treated patients, SVR was achieved in 93.4% of mono-infected and 81.4% of the co-infected group [

conclusionWith optimal HIV/HCV treatment regimens, HCC occurrence and mortality risks in co-infected patients have become comparable to those in patients with HCV mono-infection.

Indexed as

Antiviral AgentsCarcinoma, HepatocellularCoinfectionHepatitis CHepatitis C, ChronicHIV InfectionsLiver CirrhosisLiver NeoplasmsAdultDisease ProgressionDrug Therapy, CombinationFemaleHepacivirusHumansMaleMiddle AgedAntiviral AgentsDirect-acting antiviralsHepatocellular carcinomaLiver fibrosisOverall survivalPeginterferon

Identifiers

PMID41640617
PMCPMC12865366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.